Anionos Aminos CJC IPA represents a dual-peptide combination incorporating CJC-1295 and Ipamorelin, widely evaluated in preclinical models to explore synergistic somatotroph receptor signaling and growth hormone axis modulation. Designed strictly for in vitro assays and laboratory investigation, this research-grade compound allows investigators to analyze dual-pathway pituitary stimulation without confounding native feedback loops.
Anionos Aminos CJC IPA represents a dual-peptide combination incorporating CJC-1295 and Ipamorelin, widely evaluated in preclinical models to explore synergistic somatotroph receptor signaling and growth hormone axis modulation. Designed strictly for in vitro assays and laboratory investigation, this research-grade compound allows investigators to analyze dual-pathway pituitary stimulation without confounding native feedback loops.
Anionos Aminos CJC IPA is a specialized laboratory research formulation pairing two distinct synthetic secretagogues: CJC-1295 (a modified growth hormone-releasing hormone analog) and Ipamorelin (a selective ghrelin receptor agonist). Designed strictly for laboratory research use, this combination peptide conjugate allows investigators to examine the concurrent activation of Growth Hormone-Releasing Hormone Receptors (GHRH-R) and Growth Hormone Secretagogue Receptors (GHSR-1a) in cell culture and animal models.
By combining a long-acting GHRH agonist with a highly selective pentapeptide GH secretagogue, researchers can observe how dual receptor occupancy impacts downstream cellular cascades, including IGF-1 gene expression, nitrogen retention markers, and somatic cellular proliferation. Across our catalog of all peptides, this dual-pathway approach remains one of the most thoroughly documented frameworks for investigating regulated somatotropic signaling in controlled experimental settings.
To understand the experimental utility of Anionos Aminos CJC IPA, investigators must evaluate the individual biophysical properties of its constituent peptides. CJC-1295 is a 29-amino acid tetrasubstituted peptide analog of human growth hormone-releasing hormone (GHRH 1-29). In modified forms, CJC-1295 incorporates specific amino acid substitutions at positions 2, 8, 15, and 27 to protect against cleavage by endogenous dipeptidyl peptidase IV (DPP-IV), substantially prolonging its molecular half-life in laboratory assays relative to native GHRH.
Conversely, Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It acts as a potent, selective agonist at the ghrelin receptor (GHSR-1a). Unlike early-generation ghrelin mimetics, preclinical assays demonstrate that Ipamorelin binds GHSR-1a without inducing significant transcription of adrenocorticotropic hormone (ACTH), cortisol, or prolactin. When combined in the CJC-1295 Ipamorelin blend, these distinct mechanisms operate complementarily to stimulate pulsatile somatotroph secretion.
In vitro receptor binding assays indicate that the co-administration of a GHRH-R agonist and a GHSR-1a agonist produces a synergistic—rather than additive—release of growth hormone from anterior pituitary somatotrophs. Preclinical studies suggest that GHRH-R activation triggers adenylate cyclase, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). Concurrently, GHSR-1a activation by Ipamorelin stimulates phospholipase C (PLC), initiating the inositol trisphosphate (IP3) and diacylglycerol (DAG) pathway to mobilize intracellular calcium ions (Ca2+).
The convergence of elevated cAMP and intracellular calcium influx creates a pronounced amplification of exocytotic vesicle release. Detailed evaluations within our research library highlight how this dual activation mimics physiological pulsatility in animal models while minimizing receptor downregulation. Researchers utilizing the CJC-1295 and Ipamorelin guide can monitor these signal transduction pathways to assess kinetic responses under varying concentration gradients.
Laboratory investigations into Anionos Aminos CJC IPA focus primarily on metabolic rate, tissue regeneration parameters, and cellular protein synthesis. In rodent models, researchers observing dual GHRH/GHSR activation report increased circulating concentrations of insulin-like growth factor 1 (IGF-1) and improved nitrogen balance within skeletal muscle tissue preparations. In vitro data indicate that elevated local IGF-1 concentrations promote satellite cell activation and myoblast proliferation.
Furthermore, preclinical research models involving lipid metabolism demonstrate that sustained somatotroph signaling enhances lipolysis by upregulating hormone-sensitive lipase (HSL) expression in adipocytes. Because Ipamorelin selectively targets somatotropin production without altering thyroid-stimulating hormone or gonadotropin pathways, researchers can isolate the exact metabolic pathways driven by elevated growth hormone and IGF-1 vectors in experimental cohorts.
When designing comparative secretagogue protocols, researchers frequently compare the CJC-1295 and Ipamorelin dynamic to other synthetic peptides targeting the somatotropic axis. For instance, Tesamorelin is a stabilized GHRH analog featuring a trans-3-hexenoic acid group, engineered primarily for targeted visceral adipose research, whereas CJC-1295 offers broader GHRH-R stimulation. Comparing these agents alongside Sermorelin, an unmodified 29-amino acid GHRH fragment with a significantly shorter biological half-life, illustrates how chemical modification alters receptor occupancy time and plasma stability.
Similarly, while Ipamorelin provides targeted GHSR-1a binding, older compounds like GHRP-6 display broader receptor interactions that frequently trigger secondary neuroendocrine responses, including ghrelin-mediated appetite signaling in animal models. For detailed comparative data on these structural nuances, investigators can consult the Ipamorelin mechanism overview and the Tesamorelin vs CJC-1295 analysis.
Ensuring experimental reproducibility requires rigorous analytical validation of all research peptides. Prior to deployment in cellular or preclinical trials, Anionos Aminos CJC IPA must undergo independent testing via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). RP-HPLC quantifies chemical purity by separating the primary peptide sequences from synthesis-related truncated sequences or oxidation products, establishing a minimum benchmark of 99.0% purity.
Mass spectrometry confirms exact molecular weight and identity, verifying that the peptide sequence matches theoretical molecular mass down to fractional Daltons. PX1 Research provides a lot-specific Certificate of Analysis (COA) with every shipment. Every COA details the RP-HPLC chromatogram, mass spectra verification, net peptide content, and batch identification, allowing laboratory personnel to verify physical specifications prior to initiating reconstituted fluid assays.
Anionos Aminos CJC IPA is supplied as a lyophilized (freeze-dried) cake or powder inside vacuum-sealed glass vials. To preserve tertiary structural integrity and prevent enzymatic or hydrolytic degradation, lyophilized peptides should be stored in a controlled freezer environment at -20°C or -80°C away from direct light exposure. Vials should be allowed to equilibrate to ambient room temperature prior to reconstitution to minimize moisture condensation on the internal glass wall.
Reconstitution for laboratory research must be performed under aseptic conditions within a laminar flow hood. Bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free water is typically introduced gently down the inner glass wall of the vial to avoid agitating the delicate peptide matrix. The solution should be allowed to dissolve naturally without vigorous shaking or vortexing, which can cause protein shearing or aggregation. Once reconstituted, liquid solutions should be aliquoted into single-use polypropylene tubes and maintained at 2°C to 8°C for short-term experimentation or frozen at -80°C for extended storage cycles.
For sensitive cell culture assays and in vivo rodent models, controlling trace contamination is as critical as chemical purity. Bacterial endotoxins—lipopolysaccharides (LPS) derived from Gram-negative bacterial cell walls—can induce unwanted inflammatory responses in cell culture, skewing experimental results and confounding signaling data. PX1 Research subjects all peptide lots to Limulus Amebocyte Lysate (LAL) endotoxin testing, ensuring levels fall strictly below rigorous threshold limits (<0.01 EU/mg).
All manufacturing and analytical testing activities take place within USA-based, GMP-compliant facilities operating alongside ISO 17025 accredited testing laboratories. This multi-layered quality control framework guarantees complete lot traceability, sterile handling protocols, and chemical consistency across every batch shipped to research institutes, university laboratories, and commercial R&D facilities.
Acquiring high-purity research materials requires transparent vendor verification, consistent lot-to-lot reliability, and streamlined institutional supply chains. PX1 Research maintains centralized inventory management facilities in California and Arizona, facilitating same-day fulfillment for orders placed Monday through Friday before cut-off times. All research compounds are packaged in temperature-controlled, shock-absorbent materials to protect product stability during transit.
For high-volume screening projects, long-term animal studies, or multi-department research programs, institutional buyers can establish a dedicated account through our wholesale peptide portal. Bulk procurement accounts gain direct access to custom batch production, reserved lot allocation, and dedicated technical support, ensuring uninterrupted access to fully characterized, laboratory-grade compounds.
What is Anionos Aminos CJC IPA used for in research?
Anionos Aminos CJC IPA is supplied strictly as a research-grade compound for laboratory experimentation. It is used in cellular and animal models to investigate dual-receptor stimulation of the growth hormone axis via GHRH-R and GHSR-1a activation.
What peptides are contained in the Anionos Aminos CJC IPA blend?
This research formulation contains CJC-1295 (a tetrasubstituted GHRH 1-29 analog) and Ipamorelin (a selective ghrelin receptor agonist pentapeptide).
How does PX1 Research verify the purity of CJC-1295 and Ipamorelin?
PX1 Research verifies every lot using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm ≥99% purity and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular identity.
Where are PX1 Research peptides manufactured and tested?
All PX1 Research peptides are manufactured in USA-based GMP-compliant facilities and tested in ISO 17025 accredited partner laboratories to ensure strict quality standards.
What are the recommended storage conditions for lyophilized peptide vials?
Lyophilized peptide vials should be stored at -20°C to -80°C in a dry, dark environment. Prior to reconstitution, vials should reach room temperature to prevent condensation during handling.
What liquid medium should be used for laboratory reconstitution?
Laboratories typically utilize bacteriostatic water (0.9% benzyl alcohol) or sterile endotoxin-free water under aseptic conditions within a laminar flow hood to reconstitute freeze-dried peptides.
What are the endotoxin limits for PX1 Research compounds?
PX1 Research compounds undergo LAL testing to ensure endotoxin levels remain below strictly monitored research limits (<0.01 EU/mg), preventing unwanted cellular inflammatory responses.
Can institutional laboratories purchase Anionos Aminos CJC IPA in bulk?
Yes, verified academic, commercial, and institutional research facilities can establish wholesale accounts through our wholesale portal for bulk ordering and reserved lot availability.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.